Beta-blockade in cardiac arrest

Phase 2

Recruiting

• Conditions: cardiac arrest, ventricular fibrillation

• Registration Number: 2024-518949-14-00
• Lead Sponsor: Medical University Of Vienna

Brief Summary

To demonstrate that add-on treatment with landiolol in patients

with cardiac arrest significantly decreases the time to sustained

ROSC (sROSC) (time from infusion of study medication to sustained

ROSC)

Detailed Description

Not available

Study Timeline

• Study First Posted: 2024-12-10
• Last Update Posted: 2024-12-10

Recruitment & Eligibility

• Status: Ongoing, recruiting
• Sex: Not specified
• Target Recruitment: 48

Inclusion Criteria

OHCA , ³ 18 years of age • 3 or more shockable rhythms (VF or pVT) and last rhythm shockable

Exclusion Criteria

Age > 85a • Severe head trauma or acute active bleeding • Known allergy or insensitivity to landiolol or another b-blocker

Study & Design

• Study Type: Not specified
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Time (in minutes) to sustained return of spontaneous circulation		Time (in minutes) to sustained return of spontaneous circulation

Secondary Outcome Measures

Name	Time	Method
cummulative ROSC, temporary ROSC, sustained ROSC, survival at 24h, favorable neurologic outcome		cummulative ROSC, temporary ROSC, sustained ROSC, survival at 24h, favorable neurologic outcome

Trial Locations

Locations (1)

Medical University Of Vienna; 🇦🇹 Vienna, Austria

Medical University Of Vienna

🇦🇹Vienna, Austria

Michael Holzer

Site contact

+4314040029810

michael.holzer@meduniwien.ac.at